Table-2.
Availble Vaccines for SARS-CoV-2 (A-Z order).
| S.No | Name of Vaccine | Type of Vaccine | Manufacturer |
|---|---|---|---|
| 1 | Ad26.COV2.S | Recombinant, replication-incompetent adenovirus type 26 (Ad26) vectored vaccine encoding the (SARS-CoV-2) Spike (S) protein | Janssen Pharmaceuticals, Netherlands and Johnson & Johnson, USA |
| 2 | AZD1222 | Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2 | SKBIO- AstraZeneca |
| 3 | BNT162b2/COMIRNATY Tozinameran (INN) | Nucleoside modified mRNA | Pfizer |
| 4 | COVAXIN | SARS-CoV-2 Vaccine, Inactivated (Vero Cell | Bharat Biotech, India |
| 5 | Covishield (ChAdOx1_nCoV19) | Recombinant ChAdOx1 adenoviral vector encoding the Spike protein antigen of the SARS-CoV-2 | Serum Institute of India |
| 6 | mRNA-1273 | mRNA-based vaccine encapsulated in a lipid nanoparticle (LNP) | Moderna |
| 7 | SARS-CoV-2 Vaccine (Vero Cell), Inactivated (lnCoV) | Inactivated, produced in Vero cells | Sinopharm, China |
| Clinical trials-Vaccines | |||
| 8 | Ad5-nCoV | Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) | CanSino Biologics, Chinese |
| 9 | EpiVacCorona | Peptide antigen | Vector State Research Center of Virology and Biotechnology, Russian |
| 10 | Inactivated SARS-CoV-2 Vaccine (Vero Cell) | Inactivated, produced in Vero cells | Sinopharm, China |
| 11 | NVX-CoV2373/Covovax | Recombinant nanoparticle prefusion spike protein formulated with Matrix-M™ adjuvant | Novavax, USA |
| 12 | Recombinant Novel Coronavirus Vaccine （CHO Cell) | Recombinant protein subunit | ZhifeiLongcom, China |
| 13 | SARS-CoV-2 Vaccine, Inactivated (Vero Cell) | Inactivated | IMBCAMS, China |
| 14 |
SCB-2019 |
Novel recombinant SARS-CoV-2 Spike (S)-Trimer fusion protein | Novel recombinant SARS-CoV-2 Spike (S)-Trimer fusion protein |
| 15 | Soberana 01,Soberana 02 Soberana Plus | SARS-CoV-2 spike protein conjugated chemically to meningococcal B or tetanus toxoid or Aluminum | BioCubaFarma, Cuba |
| 16 | Sputnik V | Human Adenovirus Vector-based Covid-19 vaccine | Gamaleya Research Institute of Epidemiology and Microbiology, Russian |
| 17 | Zorecimeran (INN) | mRNA-based vaccine encapsulated in a lipid nanoparticle (LNP) | CureVac, German |